Exclusive Xarelto Leads for Mass Tort Law Firms
Thousands of patients prescribed Xarelto (rivaroxaban) suffered serious, life-threatening bleeding events with no antidote available at the time. Pingtree Systems connects mass tort firms with pre-qualified Xarelto claimants who had an overnight hospital stay for a documented bleeding event — delivered exclusively to your firm in real time.
What Is Xarelto (Rivaroxaban)?
Xarelto — the brand name for rivaroxaban — is an anticoagulant (blood thinner) medication developed by Bayer AG and marketed in the United States jointly by Janssen Pharmaceuticals, a subsidiary of Johnson & Johnson. Approved by the FDA in 2011, Xarelto belongs to a newer class of anticoagulants known as direct oral anticoagulants (DOACs) and was aggressively marketed as a more convenient alternative to Warfarin — the long-established blood thinner that requires regular blood monitoring and dietary restrictions.
Xarelto works by blocking Factor Xa, a protein critical to the blood-clotting process, thereby preventing dangerous clots from forming. It was prescribed for a wide range of medical conditions including atrial fibrillation, deep vein thrombosis (DVT), pulmonary embolism, and stroke prevention following hip or knee replacement surgery. At its peak, Xarelto was one of the most prescribed anticoagulant medications in the world, with over 27 million US prescriptions annually.
⚠️ The Critical Safety Problem — No Antidote Available
Unlike Warfarin, which can be rapidly reversed using Vitamin K in the event of dangerous bleeding, Xarelto had no FDA-approved antidote for the majority of its commercial life. When patients taking Xarelto experienced serious bleeding events — whether from trauma, surgery, or spontaneous internal bleeding — physicians had no reliable mechanism to quickly reverse the drug's anticoagulant effects. This inability to control bleeding turned what might have been manageable incidents into life-threatening or fatal medical crises for thousands of patients.
The Xarelto Litigation Landscape
Xarelto became the subject of one of the largest pharmaceutical mass tort litigations in American legal history. Tens of thousands of patients and their families filed lawsuits against Bayer and Janssen alleging that the manufacturers failed to adequately warn prescribing physicians and patients about the risk of serious, uncontrollable bleeding — and concealed known risks during the drug's clinical trial and approval process.
The litigation was consolidated as a Multi-District Litigation (MDL) in the Eastern District of Louisiana under MDL No. 2592. After years of litigation and thousands of filed cases, Bayer and Janssen reached a landmark $775 million settlement in 2019, resolving approximately 25,000 pending US lawsuits. This settlement represented one of the largest mass tort pharmaceutical resolutions in recent history — and underscored the severity of the injuries patients had suffered and the genuine liability exposure the manufacturers faced.
Xarelto litigation represents one of the largest pharmaceutical mass tort campaigns in US legal history, with thousands of claimants eligible for compensation.
Why Xarelto Remains a High-Value Mass Tort Campaign
Despite the major 2019 settlement, Xarelto litigation continues to generate significant case volume. New injury periods, ongoing prescriptions, and international litigation campaigns mean that qualified claimants continue to come forward. Mass tort firms with established Xarelto practices — as well as firms entering this space for the first time — benefit from one of the most clearly defined injury profiles, documented manufacturer liability, and established case values in pharmaceutical mass tort law. Pingtree Systems connects these firms with pre-qualified claimants who meet the specific eligibility criteria that drive successful case outcomes.
Medical Conditions Xarelto Was Prescribed For
Understanding which conditions Xarelto was prescribed for helps your intake team quickly assess whether a claimant's use of the drug was consistent with the claims they are making. Pingtree Systems captures and segments leads by the underlying medical condition for which Xarelto was prescribed:
Atrial Fibrillation (AFib)
Prescribed to reduce the risk of stroke in patients with non-valvular atrial fibrillation — the most common indication and the largest source of Xarelto claimants.
Deep Vein Thrombosis (DVT)
Prevention and treatment of blood clots forming in deep veins, particularly following prolonged immobility, surgery, or medical conditions affecting blood flow.
Pulmonary Embolism (PE)
Treatment of blood clots that have traveled to the lungs — a life-threatening condition for which Xarelto was increasingly prescribed as a Warfarin alternative.
Post-Surgical Prophylaxis
Prevention of blood clots following hip and knee replacement surgery — one of Xarelto's initial FDA-approved indications and a high-volume prescription context.
Stroke Prevention
Reduction of stroke risk in patients with peripheral artery disease or coronary artery disease — a significant expansion of the drug's prescribed uses over time.
Venous Thromboembolism (VTE)
Prevention of recurrent venous thromboembolism in patients with a history of DVT or PE who had completed initial anticoagulant treatment.
Serious Bleeding Injuries Covered by Xarelto Litigation
The injuries at the center of Xarelto litigation are severe, often catastrophic, and in many cases fatal. Our qualification process focuses specifically on claimants who experienced documented, serious bleeding events requiring overnight hospitalization — the injury profile most strongly associated with successful case outcomes in the Xarelto MDL:
Intracranial Hemorrhage
Bleeding inside the skull or brain — the most dangerous Xarelto complication, often resulting in death, permanent disability, or severe neurological impairment.
Gastrointestinal Bleeding
Internal bleeding in the stomach, intestines, or esophagus — the most common serious bleeding event associated with Xarelto, often requiring emergency surgery and transfusions.
Epidural / Spinal Hemorrhage
Bleeding in the spinal canal, often resulting in permanent paralysis — particularly dangerous when Xarelto was used around the time of spinal anesthesia procedures.
Surgical Bleeding Complications
Uncontrollable intraoperative or post-surgical bleeding that could not be reversed due to Xarelto's anticoagulant effects and the absence of an approved antidote.
Fatal Bleeding Events
Deaths resulting from uncontrollable bleeding while on Xarelto — wrongful death claims brought by surviving family members against Bayer and Janssen.
Other Serious Hemorrhagic Events
Any major bleeding event requiring overnight hospitalization, blood transfusion, or surgical intervention while the patient was actively prescribed Xarelto.
Our Strict Xarelto Lead Qualification Criteria
Xarelto mass tort leads require extremely precise qualification to ensure case viability and maximize the value of every inquiry your firm receives. Pingtree Systems applies the following multi-point qualification framework to every Xarelto lead before distribution:
💊 Active Xarelto Prescription
The claimant must have been actively prescribed and taking Xarelto (rivaroxaban) at the time of the bleeding event — not merely prescribed but not using the medication.
🏥 Overnight Hospitalization Required
The claimant must have been admitted to a hospital overnight (minimum 24-hour inpatient stay) specifically for a diagnosed bleeding event while on Xarelto — ER visits alone do not qualify.
🩸 Diagnosed Bleeding Event
The hospitalization must have included a clinically confirmed and medically documented bleeding event directly associated with the anticoagulant effects of Xarelto.
📅 Statute of Limitations Check
The injury event must fall within the applicable statute of limitations for the claimant's state — typically 2 to 3 years from the date of injury or discovery. Expired claims are filtered out before delivery.
⚖️ No Prior Legal Representation
The claimant must not have already retained legal representation for the Xarelto injury — ensuring your firm receives only leads that represent an active, available case opportunity.
✅ Verified Contact Information
Phone number and email address are validated at the point of submission — your intake team receives confirmed contact details so the first call connects with a genuine, reachable claimant.
Xarelto Lead Qualification Checklist
-
Prescribed and actively taking Xarelto (rivaroxaban) at the time of the injury
-
Suffered a diagnosed bleeding event while on Xarelto
-
Required an inpatient overnight hospital stay of at least 24 hours for the bleeding event
-
Injury occurred within the applicable state statute of limitations
-
Has not yet retained legal representation for this injury
-
Verified phone number and confirmed email address
-
Claimants with ER visits only (no overnight admission) do not qualify
-
Claimants who have already retained an attorney are excluded
-
Claims outside the applicable statute of limitations are filtered out
Our Xarelto Lead Generation Channels
Pingtree Systems reaches Xarelto claimants through a diversified, continuously optimised digital ecosystem designed specifically for pharmaceutical mass tort case identification:
Paid Search (PPC)
Google & Bing ads targeting Xarelto patients searching for lawsuit information, bleeding injury compensation, and attorney help.
SEO & Content
Organic traffic from patients and families reading Xarelto side effects guides, lawsuit news, and compensation eligibility articles.
Display & Video Ads
YouTube and display network campaigns targeting demographics most likely to have been prescribed Xarelto — typically adults 55 and older with cardiovascular conditions.
Social Media Ads
Facebook campaigns targeting patients with AFib, heart disease, and joint replacement history who may have taken Xarelto.
Email & Retargeting
Targeted campaigns re-engaging patients who researched Xarelto lawsuits but have not yet spoken with an attorney.
Inbound Call Transfers
Live transfers from claimants calling our mass tort intake lines — ready to provide their details to an attorney immediately.
How Pingtree Systems Works
From the moment a Xarelto patient submits an inquiry to the second a verified, qualified lead arrives in your case management system, our platform manages every step automatically:
Claimant Submits a Xarelto Inquiry
A patient or family member finds one of our network's Xarelto lawsuit information pages. They complete a guided intake form confirming their Xarelto prescription status, the bleeding event they experienced, their hospitalization details, injury date, and contact information.
Multi-Point Qualification & Verification
Every submission is validated against our Xarelto-specific qualification criteria: prescription confirmation, bleeding event type, overnight hospitalization confirmation, statute of limitations check, prior representation check, and contact verification. Only leads meeting all criteria proceed to distribution.
Real-Time Ping-Post Distribution
The verified lead is pinged to registered mass tort firms whose targeting parameters match. The winning firm receives the complete verified claimant data package — prescription details, injury type, hospitalization dates, and contact information — within milliseconds via our ping-post API.
Instant Delivery & 5-Day Return Window
The lead is delivered to your CRM or intake system within 60 seconds via API push or webhook. If a claimant, upon follow-up, is found not to meet the stated qualification criteria, Pingtree Systems offers a replacement lead credit within five consecutive business days of delivery.
Analytics, Reporting & Campaign Optimisation
Monitor every lead from delivery through initial intake call, case acceptance, and docket filing in our live analytics dashboard. Your dedicated account manager reviews performance and continuously refines qualification criteria and targeting to maximise your cost per docketed Xarelto case.
Why Mass Tort Firms Choose Pingtree Systems
Leading mass tort law firms across the United States rely on Pingtree Systems for Xarelto claimant acquisition. Here is what sets our platform apart from generic mass tort lead vendors:
- ✓
100% exclusive leads — every Xarelto lead is delivered to one firm only. No competing firms calling the same claimant simultaneously.
- ✓
Strict multi-point qualification — only claimants who meet all Xarelto-specific criteria (prescription, overnight hospitalization, documented bleeding, SOL check, no prior representation) reach your intake team.
- ✓
Real-time delivery under 60 seconds — leads arrive while claimants are actively engaged and before they speak with competing firms or lose interest.
- ✓
5-day replacement guarantee — if a delivered lead fails to meet the stated qualification criteria on follow-up, we provide a replacement credit within five business days.
- ✓
TCPA-compliant data collection — all leads obtained with documented claimant consent at the point of submission, protecting your firm from regulatory exposure.
- ✓
Flexible volume and budget controls — scale Xarelto lead intake up or down based on your firm's case acceptance capacity and MDL filing timelines.
- ✓
No contracts, pay-per-lead pricing — zero fixed commitments, minimum volumes, or long-term campaign obligations.
- ✓
Dedicated mass tort account management — a specialist account manager monitors lead quality and works with your intake team to maximise case acceptance rates.
Explore Our Other Mass Tort Lead Categories
Pingtree Systems operates one of the most comprehensive mass tort lead generation networks in the United States. Alongside Xarelto, we generate pre-qualified claimant leads for all major active and emerging mass tort campaigns:
Frequently Asked Questions About Xarelto mass tort Leads
Ready to Grow Your Xarelto Mass Tort Docket?
Connect with pre-qualified Xarelto claimants who suffered documented bleeding events and meet every qualification criterion — delivered exclusively to your firm in real time.